Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.Dec.19

News

OBI Pharma and TegMine Therapeutics Sign Commercial License Agreement for Glycoprotein-Targeting ADC

2025.Dec.18

News

OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation

2025.Dec.09

News

OBI Pharma Presents Preclinical Results for Bispecific ADC OBI-201 at SABCS 2025

Read More

2025.Dec.19

Announcement

The Company’s BOD resolved to enter into commercial licensing agreement with TegMine for the development of glycoprotein monoclonal antibody ADC

2025.Dec.19

Announcement

Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officer

2025.Dec.19

Announcement

Announcement pursuant to Article 22.1(3) of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

2024 Annual Report

Learn how we created value in 2024 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2025 Investors' Meeting - Driving Value Transformation Through ADC Innovation

Download PDF

Read More

2025 First Extraordinary General Shareholders’ Meeting

  • 2025.Oct.20 at 09:00 AM
  • Taipei Bioinnovation Park 1F Conference Room
Youtube

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact